Processa Pharmaceuticals: Clinical Trials

5 trials sponsored by Processa Pharmaceuticals, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 terminated. 5 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Completed 4, Terminated 1
Phase 23Completed 2, Terminated 1

Follow Processa Pharmaceuticals: new trials by email

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors
PCS6422 and capecitabine - Advanced Cancer, Refractory Cancer
Phase 1CompletedProcessa Pharmaceuticals232021-06-182024-10-10
Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects
PCS499, Trental - Healthy
Phase 1CompletedProcessa Pharmaceuticals182018-02-262019-02-12
RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
RX-3117 - Metastatic Pancreatic Cancer
Phase 1 / Phase 2CompletedProcessa Pharmaceuticals462017-10-022023-12-06
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
RX-3117 - Solid Tumor, Metastatic Bladder Cancer
Phase 1 / Phase 2CompletedProcessa Pharmaceuticals1272013-12-012023-12-06
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy
HT-100 - Duchenne Muscular Dystrophy
Phase 1 / Phase 2TerminatedProcessa Pharmaceuticals172013-05-012020-09-03

Conditions studied

Neoplasms (2)  ·  Muscular Dystrophy, Duchenne (1)  ·  Neoplasm Metastasis (1)  ·  Pancreatic Neoplasms (1)  ·  Stomach Neoplasms (1)  ·  Urinary Bladder Neoplasms (1)

Interventions

fluorocyclopentenylcytosine (2)  ·  Albumin-Bound Paclitaxel (1)  ·  Capecitabine (1)  ·  Pentoxifylline (1)

Countries

United States (4)  ·  United Kingdom (1)

Top investigators

Ely Benaim, MD (2)  ·  Diana M Escolar, MD (1)  ·  Sharan Sidhu, MBChB (1)  ·  Sian Bigora, Pharm. D (1)